Arginase I, polyamine, and prostaglandin E2 pathways suppress the inflammatory response and contribute to diffuse cutaneous leishmaniasis

Journal of Infectious Diseases

Volumn 211, Issue 3, 2015, Pages 426-435

  França Costa, Jaqueline ^a   Van Weyenbergh, Johan ^a   Boaventura, Viviane S ^a,b   Luz, Nívea F ^a,b   Malta Santos, Hayna ^a,b   Oliveira, Murilo Cezar Souza ^a,b   De Campos, Daniela Conceição Santos ^a,b   Saldanha, Ana Cristina ^c   Dos Santos, Washington L C ^a   Bozza, Patrícia T ^a   Barral Netto, Manoel ^a,b,d   Barral, Aldina ^a,b,d   Costa, Jackson M ^a   Borges, Valeria M ^a,b,d  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c FEDERAL UNIVERSITY OF MARANHÃO   (Brazil)

^d Instituto Nacional de Ciencia e Tecnologia de Investigacao em Imunologia III INCT   (Brazil)

Author keywords

arginase I; diffuse cutaneous leishmaniasis; Leishmania amazonensis; ornithine decarboxylase; prostaglandin E2; TGF

Indexed keywords

ARGINASE 1; CYCLOOXYGENASE 2; ORNITHINE DECARBOXYLASE; POLYAMINE; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; ARGINASE; ARGINASE I, HUMAN; TRANSCRIPTOME;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE CUTANEOUS LEISHMANIASIS; ENZYME BLOOD LEVEL; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LEISHMANIA; LOCALIZED CUTANEOUS LEISHMANIASIS; MACROPHAGE; MALE; POLYAMINE SYNTHESIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN LEISHMANIASIS; BLOOD; CHILD; GENETICS; INFLAMMATION; METABOLISM; MIDDLE AGED; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ARGINASE; CHILD; CHILD, PRESCHOOL; DINOPROSTONE; FEMALE; HUMANS; INFLAMMATION; LEISHMANIASIS, DIFFUSE CUTANEOUS; MALE; MIDDLE AGED; ORNITHINE DECARBOXYLASE; POLYAMINES; SIGNAL TRANSDUCTION; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; YOUNG ADULT;

EID: 84922553393     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu455     Document Type: Article

References (40)

1. Silveira FT, Lainson R, Corbett CE. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: a review. Mem Inst Oswaldo Cruz 2004; 99:239-51.
2. Carvalho EM, Barral A, Costa JM, Bittencourt A, Marsden P. Clinical and immunopathological aspects of disseminated cutaneous leishman-iasis. Acta tropica 1994; 56:315-25.
3. Costa JM, Saldanha AC, Silva CM, et al. Spontaneous regional healing of extensive skin lesions in diffuse cutaneous Leishmaniasis (DCL). Rev Soc Bras Med Trop 1995; 28:45-7.
4. Vincendeau P, Gobert AP, Daulouede S, Moynet D, Mossalayi MD. Arginases in parasitic diseases. Trends Parasitol 2003; 19:9-12.
5. Abebe T, Hailu A, Woldeyes M, et al. Local increase of arginase activity in lesions of patients with cutaneous leishmaniasis in Ethiopia. PLoS Negl Trop Dis 2012; 6:e1684.
6. Iniesta V, Gomez-Nieto LC, Corraliza I. The inhibition of arginase by N (omega)-hydroxy-l-arginine controls the growth of Leishmania inside macrophages. J Exp Med 2001; 193:777-84.
7. Kaur K, Emmett K, McCann PP, Sjoerdsma A, Ullman B. Effects of DL-alpha-difluoromethylornithine on Leishmania donovani promastigotes. J Protozool 1986; 33:518-21.
8. Bittencourt A, Barral A, de Jesus AR, de Almeida RP, Grimaldi Junior G. In situ identification of Leishmania amazonensis associated with diffuse cutaneous leishmaniasis in Bahia, Brazil. Memorias do Instituto Oswaldo Cruz 1989; 84:585-6.
9. Barral-Netto M, Barral A, Brownell CE, et al. Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 1992; 257:545-8.
10. Guimaraes ET, Santos LA, Ribeiro dos Santos R, Teixeira MM, dos Santos WL, Soares MB. Role of interleukin-4 and prostaglandin E2 in Leishmania amazonensis infection of BALB/c mice. Microbes Infect 2006; 8:1219-26.
11. Lacerda DI, Cysne-Finkelstein L, Nunes MP, et al. Kinetoplastid membrane protein-11 exacerbates infection with Leishmania amazonensis in murine macrophages. Memorias do Instituto Oswaldo Cruz 2012; 107:238-45.
12. Convit J, Pinardi ME, Rondon AJ. Diffuse cutaneous leishmaniasis: a disease due to an immunological defect of the host. Trans R Soc Trop Med Hyg 1972; 66:603-10.
13. Barral A, Pedral-Sampaio D, Grimaldi Junior G, et al. Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am J Trop Med Hyg 1991; 44:536-46.
14. Abebe T, Takele Y, Weldegebreal T, et al. Arginase activity-a marker of disease status in patients with visceral leishmaniasis in ethiopia. PLoS Negl Trop Dis 2013; 7:e2134.
15. Boaventura VS, Santos CS, Cardoso CR, et al. Human mucosal leish-maniasis: neutrophils infiltrate areas of tissue damage that express high levels of Th17-related cytokines. Eur J Immunol 2010; 40:2830-6.
16. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008; 26:317-25.
17. Afonso L, Borges VM, Cruz H, et al. Interactions with apoptotic but not with necrotic neutrophils increase parasite burden in human macro-phages infected with Leishmania amazonensis. J Leukoc Biol 2008; 84:389-96.
18. Franca-Costa J, Wanderley JL, Deolindo P, et al. Exposure of phospha-tidylserine on Leishmania amazonensis isolates is associated with diffuse cutaneous leishmaniasis and parasite infectivity. PloS One 2012; 7:e36595.
19. Moens B, Pannecouque C, López G, et al. Virol J 2012; 9:171.
20. Khouri R, Silva Santos G, Soares G, et al. SOD1 plasma level as a bio-marker for therapeutic failure in cutaneous leishmaniasis. J Infect Dis 2014; 210:306-10.
21. Cloke TE, Garvey L, Choi BS, et al. Increased level of arginase activity correlates with disease severity in HIV-seropositive patients. J Infect Dis 2010; 202:374-85.
22. Elgun S, Kumbasar H. Increased serum arginase activity in depressed patients. Prog Neuro-psychopharmacol Biol Psychiatry 2000; 24: 227-32.
23. Li H, Romieu I, Sienra-Monge JJ, et al. Genetic polymorphisms in argi-nase I and II and childhood asthma and atopy. J Allergy Clin Immunol 2006; 117:119-26.
24. Dumont J, Zureik M, Cottel D, et al. Association of arginase 1 gene polymorphisms with the risk of myocardial infarction and common carotid intima media thickness. J Med Genet 2007; 44:526-31.
25. Corraliza IM, Soler G, Eichmann K, Modolell M. Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine bone-marrow-derived macrophages. Biochem Biophys Res Commun 1995; 206:667-73.
26. Iniesta V, Gomez-Nieto LC, Molano I, et al. Arginase I induction in macrophages, triggered by Th2-type cytokines, supports the growth of intracellular Leishmania parasites. Parasite Immunol 2002; 24:113-8.
27. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007; 282:11613-7.
28. Kaul V, Van Kaer L, Das G, Das J. Prostanoid receptor 2 signaling protects T helper 2 cells from BALB/c mice against activation-induced cell death. J Biolo Chem 2012; 287:25434-9.
29. Serezani CH, Chung J, Ballinger MN, Moore BB, Aronoff DM, Peters-Golden M. Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase. Am J Respir Cell Mol Biol 2007; 37:562-70.
30. Rieser C, Bock G, Klocker H, Bartsch G, Thurnher M. Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J Exp Med 1997; 186:1603-8.
31. Bekeredjian-Ding I, Schafer M, Hartmann E, et al. Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha. Immunology 2009; 128:439-50.
32. Betz M, Fox BS. Prostaglandin E2 inhibits production of Th1 lympho-kines but not of Th2 lymphokines. J Immunol 1991; 146:108-13.
33. Baratelli F, Lee JM, Hazra S, et al. PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer. Am J Transl Res 2010; 2:356-67.
34. Matsumura T, Suzuki T, Aizawa K, et al. Regulation of transforming growth factor-beta-dependent cyclooxygenase-2 expression in fibro-blasts. J Biol Chem 2009; 284:35861-71.
35. Boutard V, Havouis R, Fouqueray B, Philippe C, Moulinoux JP, Baud L. Transforming growth factor-beta stimulates arginase activity in macro-phages. Implications for the regulation of macrophage cytotoxicity. J Immunol 1995; 155:2077-84.
36. Gobert AP, Daulouede S, Lepoivre M, et al. L-Arginine availability modulates local nitric oxide production and parasite killing in experimental trypanosomiasis. Infect Immun 2000; 68:4653-7.
37. Van Nieuwenhove S, Schechter PJ, Declercq J, Bone G, Burke J, Sjoerdsma A. Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial. Trans R Soc Trop Med Hyg 1985; 79:692-8.
38. Boitz JM, Yates PA, Kline C, et al. Leishmania donovani ornithine de-carboxylase is indispensable for parasite survival in the mammalian host. Infect Immun 2009; 77:756-63.
39. Ribeiro-Gomes FL, Otero AC, Gomes NA, et al. Macrophage interactions with neutrophils regulate Leishmania major infection. J Immunol 2004; 172:4454-62.
40. Balestieri FM, Queiroz AR, Scavone C, Costa VM, Barral-Netto M, Abrahamsohn Ide A. Leishmania (L.) amazonensis-induced inhibition of nitric oxide synthesis in host macrophages. Microbes Infect 2002; 4:23-9.